Search clinical trials for: Epoetin alfa/beta

Total 8928 results

Seoul National University Bundang Hospital

Completed

Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery (EPO-CABG)

Kidney Failure, Acute

Korea, Republic of
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis

Anemia

France
Hoffmann-La Roche

Completed

STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients

Anemia

Czech Republic
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Anemia

Estonia, Latvia, Finland, Norway
University of Copenhagen
Rigshospitalet, Denmark

Completed

Renal Effects of Erythropoietin in Humans (EPO 2012)

Renal Effects

Denmark
Amgen

Terminated

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

Chronic Kidney Disease
National Institute on Aging (NIA)

Completed

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Acute ST Elevation Myocardial Infarction

United States
Janssen-Ortho Inc., Canada

Withdrawn

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Anemia | Blood Transfusion | Orthopedic Surgery
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Stanford University
National Institute on Aging (NIA)

Withdrawn

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

Anemia

United States
University Medical Center Groningen
Janssen-Cilag Ltd.; The Interuniversity Cardiology Institute of the Netherlands

Completed

Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction (HEBEIII)

Myocardial Infarction

Netherlands
European Organisation for Research and Treatment...
Charite University, Berlin, Germany; Trans Tasman Radiation Oncology Group; Groupe... and other collaborators

Terminated

Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

France, Belgium, Israel, United Kingdom, Australia, Spain, Germany, Switzerland, Hungary, Netherlands
Northwestern University
National Cancer Institute (NCI)

Completed

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Fatigue | Anemia | Unspecified Adult Solid Tumor, Protocol Specific

United States
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS); PPD; Ortho Biotech...

Withdrawn

Epoetin Alfa for HIV-Associated Neuropathy Trial

HIV Infections | Neuropathy
University Hospital, Angers

Completed

Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C

Chronic Hepatitis C

France
Australian and New Zealand Intensive Care Research...
Monash University

Completed

Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury

Traumatic Brain Injury

Australia
Hillerod Hospital, Denmark
Aarhus University Hospital; Rigshospitalet, Denmark; Maastricht University Medical... and other collaborators

Completed

Treatment With Erythropoietin and Cognition During Hypoglycaemia

Hypoglycemia | Type 1 Diabetes

Denmark
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy

Acquired Immunodeficiency Syndrome | Anemia
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Anemia

France, United Kingdom, Germany, Spain, Belgium, Italy
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Anemia

Hungary
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France
M.D. Anderson Cancer Center
Ortho Pharmaceuticals

Terminated

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

Rectal Cancer | Gastrointestinal Cancer

United States
Ortho Pharmaceuticals

Completed

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

HIV Infections | Cytopenias

United States
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

HIV Infections | Cytopenias

United States
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

HIV Infections | Cytopenias

United States
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Renal Anemia, Chronic

Italy, Spain, Hong Kong, Taiwan, Hungary, Korea, Republic of, Australia, Canada, France, Germany, Greece, Belgium, Thailand, Poland, Russian Federation, Israel
Bio Sidus SA
IC RESEARCH GROUP

Completed

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia

Antineoplastic Chemotherapy Induced Anemia

Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

Acquired Immunodeficiency Syndrome | Anemia
R W Johnson Pharmaceutical Research Institute

Completed

Treatment Program for Anemia in AIDS Patients

HIV Infections | Cytopenias

United States
Ortho Pharmaceuticals

Completed

The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT

HIV Infections | Cytopenias

United States
Hoffmann-La Roche

Completed

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Anemia

Italy, Spain, Australia, France, Canada, Germany, United Kingdom, Belgium, Austria, Switzerland, Netherlands, Denmark, Finland, Portugal
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

Head and Neck Cancer | Anemia

United States, Canada, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Hemostasis, Surgical
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Neoplasms | Anemia
Hoffmann-La Roche

Completed

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Anemia

Belgium, Italy, Spain, France, Sweden, Greece, United Kingdom, United States, Australia, Canada, Germany, Netherlands, Puerto Rico
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer | Fatigue | Anemia
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

HIV Infections | Cytopenias

United States
Azidus Brasil
Blau Farmaceutica S.A.

Completed

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Renal Insufficiency, Chronic

Brazil
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

Acquired Immunodeficiency Syndrome | Anemia
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Sandoz
Hexal AG

Completed

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. (EPO-PASS)

Chronic Kidney Disease

Poland, Germany, Romania, Italy, Austria, Bulgaria, France, Macedonia, The Former Yugoslav Republic of, Russian Federation, Ukraine
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Multiple Myeloma | Anemia | Plasma Cell Neoplasm

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Rheumatoid Arthritis | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Anemia | Chemotherapy

Search clinical trials for: Epoetin alfa/beta

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations